For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting

D. Neil Hayes; John Patrick Gleysteen; David Louis Schwartz

doi:10.1200/JCO.22.00274

For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting

D. Neil Hayes, John Patrick Gleysteen, David Louis Schwartz

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Article number	JCO.22.00274
Journal	Journal of Clinical Oncology
Volume	69
DOIs	https://doi.org/10.1200/JCO.22.00274
State	Published - Apr 1 2022
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.22.00274

Cite this

@article{a06753619c30472598c768f328adf644,

title = "For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting",

author = "Hayes, {D. Neil} and Gleysteen, {John Patrick} and Schwartz, {David Louis}",

year = "2022",

month = apr,

day = "1",

doi = "10.1200/JCO.22.00274",

language = "English (US)",

volume = "69",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting

AU - Hayes, D. Neil

AU - Gleysteen, John Patrick

AU - Schwartz, David Louis

PY - 2022/4/1

Y1 - 2022/4/1

UR - http://www.scopus.com/inward/record.url?scp=85130171701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130171701&partnerID=8YFLogxK

U2 - 10.1200/JCO.22.00274

DO - 10.1200/JCO.22.00274

M3 - Review article

C2 - 35446600

AN - SCOPUS:85130171701

SN - 0732-183X

VL - 69

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

M1 - JCO.22.00274

ER -

For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this